Telix Pharmaceuticals and Eczacibasi-Monrol Sign Manufacturing and Distribution Agreement

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution AgreementMELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. We are particularly pleased to be providing regional manufacturing services including back-up for Telix manufacturing operations in Europe, the unique strength of a Turkish company." About Telix Pharmaceuticals LimitedTelix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR). Telix Corporate Contact Dr Christian BehrenbruchTelix Pharmaceuticals Limited CEO Email: chris@telixpharma.com Telix Investor Relations Lisa WilsonIn-Site Communications Tel: +1 212 452 2793 Email: lwilson@insitecony.comSource: Telix Pharmaceuticals Limited

June 13, 2019 11:48 UTC


Tags
Cryptocurrency      African Press Release      Lifestyle       Hiring       Health-care       VMware

Loading...